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852Allogeneic Hematopoietic Stem Cell Transplantation
for Philadelphia-Positive Acute Lymphoblastic
Leukemia in Children and Adolescents: A Retrospective
Multicenter Study of the Italian Association
of Pediatric Hematology and Oncology (AIEOP)
Franca Fagioli,1 Marco Zecca,2 Carla Rognoni,3 Edoardo Lanino,4 Adriana Balduzzi,5
Massimo Berger,1 Chiara Messina,6 Claudio Favre,7 Marco Rabusin,8
Luca Lo Nigro,9 Riccardo Masetti,10 Arcangelo Prete,10 Franco Locatelli,11
on behalf of the AIEOP-HSCT GroupPhiladelphia-positive acute lymphoblastic leukemia (Ph1 ALL) still represents a major challenge. We report
the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP) with allogeneic
hematopoietic stem cell transplantation (HSCT) in children with Ph1 ALL from 1990 to 2008. Sixty-nine
patients received HSCT from either a related (37, 54%) or an unrelated (32, 46%) donor. Twenty-five patients
(36%) underwent transplantation before 2000 and 44 (64%) after 2000. Twenty-three patients (33%) received
Imatinib mesylate treatment before HSCT and seven (10%) after HSCT. After a median follow-up of 56
months, the overall survival (OS) probability was 51% (95% confidence interval [CI], 38-63), the leuke-
mia-free survival (LFS) was 47% (95% CI, 34-59), transplantation-related mortality (TRM) was 17% (95%
CI, 10-30), and relapse incidence (RI) was 36% (95% CI, 26-50). Transplantation in first complete remission,
female gender, and lower WBC count at diagnosis were associated with a better LFS in both univariate and
multivariate analyses. Patients with p210 transcript had a trend for a worse prognosis compared with those
who had the p190 transcript. Our series confirms the role of HSCT in the eradication of Ph1 ALL. Early
HSCT is recommended once morphologic remission is obtained.
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overall survival (OS) probability often \20% [4,5].
Slow early response to conventional therapy has been
reported to predict poor prognosis [6,7].
In the earlier Italian studies conducted in 1970, all
patients received a relatively low-intensity chemother-
apy and cranial radiotherapy. The first trial having
stratified patients on risk-tailored chemotherapy was
the study ‘82; however, no data are available on Ph-
positive leukemias in this cohort. It includes 902
patients from 1982 to 1987. The next study was the
Study ’87, enrolling 632 patients, but also in this study,
the Italian Association of Pediatric Hematology and
Oncology (AIEOP)-Registry have no data on event-
free survival (EFS) and OS for Ph-positive leukemia.
The enrolling time for this trial was from 1987 to
1991. In the study 88 were enrolled 396 patients only
in few AIEOP centers. This was the first Berlin-
Frankfurt-Munster–based trial, and only seven pa-
tients were diagnosed as having Ph-positive ALL.
The next AIEOP trial was conducted from 1991 to
1995: 1,192 patients were treated, and 20 had Ph-
positive ALL. The 5-year EFS reported for these pa-
tients was 35%, whereas the 5-year OS was 49.5%.
In the next AIEOP trial (AIEOP LLA 95), we treated
1,743 patients from 1995 to 2000. The 5-year EFS was
28.3%, and the OS was 41.8% for patients with Ph-
positive ALL. From 2003, the AIEOP centers enrolled
Ph-positive patients in the EsPhALL study, in which
a randomized arm received imatinib. Most of the pa-
tients received stem cell transplantation in first com-
plete remission (CR1). From 2004 to 2009, 178
patients were treated; in 2009, the randomization for
good-risk patients was closed to external evidence of
superiority of imatinib. The disease-free survival
(DFS) rate was 73% for patients who responded well
to prednisone versus 62% who responded poorly [8,9].
To date, one of the more widely applied curative
therapies for patients with Ph1 ALL is allogeneic
hematopoietic stemcell transplantation (HSCT), better
results in terms of outcome having been obtained in pa-
tients who underwent transplantation early on during
the course of the disease [10-14]. In 2000, Arico et al.
[15] reported 326 children and young adults who were
treated for Ph1 ALL. HSCT offered advantages in
terms of survival when a matched family donor
(MFD) was available, and, more importantly, the bene-
fits of HSCT increased over time, thus suggesting that
transplantation played amore effective role than contin-
uation of chemotherapy in preventing late relapse. In
2005, theBritishConsensus study confirmed the benefit
of HSCT and showed a 60% 3-year DFS for children
undergoing transplantation compared with 36% for
children who had not undergone transplantation [16].
In 2001, imatinib mesylate, a competitive inhibitor
of the bcr-abl tyrosine kinase resulting from the fusion
gene of Ph1 chronic myeloid leukemia (CML), wasapproved by the US Food and Drug Administration
as first-line treatment for patients with CML, and it
was also used to treat patients with Ph1 ALL. Later,
imatinib mesylate was added to standard chemother-
apy and allogeneic HSCT with promising results
[17,18]. Although the utility of imatinib for the
treatment of Ph1 ALL in children is less well
established, a recent Children’s Oncology Group
(COG) study reported promising results using
imatinib together with intensive chemotherapy [19].
The high risk of relapse in patients with positive
minimal residual disease (MRD) after HSCT makes
the administration of a bcr-abl-directed tyrosine kinase
inhibitor an attractive therapeutic option to reestablish
molecular negativity and prevent relapse. A recent
study showed that patients who received imatinib for
a 6-month period after related HSCT had a better 1-
year EFS compared with an untreated historic control
group [19]. However, in a recent study, Kang et al. [20]
showed that MRD is not the only predictor of relapse
or resistance after first-line therapy. Imatinib may in-
hibit the bcr-abl tyrosine kinase, but other genes may
also be involved in relapse, which can occur despite
treatment with tyrosine kinase inhibitors.
In order to evaluate the impact of allogeneic
HSCT in this very high-risk pediatric patient group,
we analyzed the outcomes of 69 consecutive patients
under the age of 20 who received myeloablative alloge-
neic HSCT for Ph1 ALL and were reported to the
AIEOP-HSCT Registry between 1990 and 2008.PATIENTS AND METHODS
Enrolled in the study were 69 patients, younger
than 20 years, affected by de novo Ph1 ALL who un-
derwent transplantation between 1990 and 2008. The
diagnosis of ALLwas established according to conven-
tional criteria. The Philadelphia chromosome t(9;22)
(q34;q11.2) or the bcr-abl fusion gene was detected by
conventional cytogenetic analysis, fluorescent in situ
hybridization, or by reverse-transcription polymerase
chain reaction.
At diagnosis, median age was 7 years (range, 1-19),
whereas median WBC count was 76  109/L (range,
30-580). Forty-nine patients were male (71%) and 20
were female (29%). The immunophenotype was
B cell precursor ALL for 67 patients (97%) and T cell
precursorALL for twopatients (3%). First-line chemo-
therapy was based on the AIEOP LLA 91 protocol for
13 patients (19%), AIEOP LLA 95 for 16 (23%), and
AIEOP LLA 2000 for 27 (39%), whereas 13 patients
received other treatment protocols (19%) (Table 1).
Karyotypes were classified according to the Inter-
national System for Human Cytogenetic Nomencla-
ture [21]. All patients in the study had successful
cytogenetic analysis at diagnosis.
Table 1. Patient and Transplantation Characteristics of the
69 Children and Adolescents Enrolled in the Study
Number of patients 69 (100%)
Gender:
M 49 (71%)
F 20 (29%)
Diagnosis:
Age at diagnosis (years, median, and range): 7 (1-19)
WBC at diagnosis (109/L): 76 (30-580)
Immunophenotype
B lineage 67 (97%)
T lineage 2 (3%)
Molecular analysis
p190 44 (64%)
p210 13 (19%)
p190/p210 5 (7%)
Unknown 7 (10%)
First-line chemotherapy
AIEOP ALL 91 13 (19%)
AIEOP ALL 95 16 (23%)
AIEOP ALL 2000 27 (39%)
OTHER PROTOCOLS 13 (19%)
Age at transplantation (years, median, and
range)
9 (1-20)
Disease status at HSCT
First remission 43 (62%)
Second remission 17 (25%)
More advanced disease 9 (13%)
Cytogenetic remission
Yes 60 (87%)
No 6 (9%)
Unknown 3 (4%)
Donor
Matched family donor 37 (54%)
Matched unrelated donor 32 (46%)
Stem cell source
Bone marrow 62 (90%)
Peripheral blood 2 (3%)
Cord blood 5 (7%)
Conditioning regimen
TBI + chemotherapy 62 (90%)
Chemotherapy alone 7 (10%)
GVHD prophylaxis MFD MUD
CyA 33 (89%) 0 (0%)
Cs-A + MTX 4 (11%) 5 (16%)
Cs-A + MTX + ATG 0 (0%) 23 (72%)
Cs-A + MTX + steroids 0 (0%) 1 (3%)
Cs-A + steroids 0 (0%) 2 (6%)
Cs-A + steroids + ATG 0 (0%) 1 (3%)
M indicates male; F, female; TBI, total-body irradiation; MFD, matched
family donor; MUD, matched unrelated donor; Cs-A, cyclosporin A;
MTX, methotrexate; ATG, antithymocyte globulins.
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bcr-abl fusion protein variant in 44 patients (64%),
the p210 form in 13 (19%), whereas five patients had
leukemia blasts expressing both the p190 and p210
transcripts (7%). Themedian age at diagnosis was sim-
ilar in p190 and p210 patients: 6.1 years (range, 3.1-19)
for p190 patients and 5.9 years (range, 3-15.9) for p210
patients (P . .05).
The presence of bcr-abl RNA copies was measured
qualitatively and/or quantitatively in some patients.
Allogeneic HSCT
Median patient age at HSCT was 9 years (range,
1-20); it was 7 (range, 2-20) and 4 years (range, 1-6)
for patients who did or did not receive total-bodyirradiation (TBI), respectively (P 5 .005). At the time
of HSCT, 43 patients were in CR1 (62%), 17 in
CR2 (25%), and nine were in a more advanced disease
phase (13%) (Table 1). All patients received a myeloa-
blative preparative regimen, mainly based on TBI
(90%), most frequently combined with thiotepa and
cyclophosphamide (33%) (Table 1).
Graft-versus-host disease (GVHD) prophylaxis
mainly consisted of cyclosporin A alone in the 37
patients who underwent transplantation from an
MFD or of a combination of cyclosporin A, short-
term methotrexate 6 antithymocyte globulin (72%)
in children given the allograft from a matched unre-
lated donor [MUD] see also Table 1 for details.
Bone marrow was the stem cell source for 62 pa-
tients (90%), whereas two patients received peripheral
blood stem cells and five patients cord blood. For pa-
tients receiving bone marrow cells, the median number
ofmononuclear cells infusedwas 3.7 108/kg (1.5-6.5).
Supportive therapy, as well as prophylaxis and
treatment of infections, were substantially homoge-
neous among centers. Broad-spectrum antibiotics
were given if the patient became febrile. Secondary an-
tifungal prophylaxis was given to patients with a known
history of fungal infections. All patients received acy-
clovir for antiviral prophylaxis. All patients received
cotrimoxazole as Pneumocystis jirovecii prophylaxis
from the day of engraftment until 3 months after the
end of immunosuppressive therapy. Granulocyte-
colony stimulating factor was not routinely used.
All parents or guardians signed the appropriate
informed consent form previously approved by the
local ethic committee or the institutional review board.
Imatinib
Twenty-three patients received imatinib mesylate
before HSCT (33%). When imatinib mesylate was
used after HSCT (seven cases), it was started at a me-
dian of 57 days after transplantation (range, 28-69) and
continued for a median of 17 months (range, 3-33).
The imatinib mesylate dosage was 300 mg/m2/day.
Definitions
The patients were considered in morphologic CR
if they had normal neutrophil and platelet counts,
\5% blast cells in a bone marrow smear, and no extra-
medullary disease. All patients had a lumbar puncture
before HSCT to document cerebrospinal fluid remis-
sion. Cytogenetic remission was defined as absence of
the Philadelphia chromosome in all metaphases ob-
tained from a bone marrow specimen.
Neutrophil and platelet engraftment were defined
as the first of 3 consecutive days with a neutrophil
count.0.5 109/L and an unsupported platelet count
.50  109/L, respectively. Acute GVHD (aGVHD)
and chronic GVHD (cGVHD) were diagnosed and
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Children with evidence of donor engraftment who
survived more than 14 days and 90 days from
transplantation were evaluated for the occurrence of
aGVHD and cGVHD, respectively. Relapse was
defined on the basis of morphologic evidence of
leukemia in bone marrow, or other extramedullary
organs. Transplantation-related mortality (TRM)
was defined as all causes of nonleukemia death occur-
ring after HSCT. OS was defined as the interval
between HSCT and death or the last follow-up, and
leukemia-free survival (LFS) was defined as the inter-
val between HSCT and relapse or TRM or the last
follow-up, whichever occurred first.Statistical Analysis
Patient-, disease-, and transplantation-related
variables were expressed as median and ranges, or as
percentage, as appropriate. The following patient- or
transplantation-related variables were analyzed for
their potential impact on outcome: gender, WBC at
diagnosis, cytogenetics, molecular analysis, disease
phase, pre-HSCT imatinib mesylate, post-HSCT
imatinib mesylate, donor type, TBI administration,
aGVHD and cGVHDoccurrence, year of transplanta-
tion (before or after 2000), and age. For the statistical
analysis, continuous variables, except age, were catego-
rized as follows: each variable was first divided into
four categories at the 25th, 50th, and 75th percentiles.
If the relative event rates (the ratio of the observed
number of events to the expected number of events
in the category) in two or more adjacent categories
(and the median time to events) did not differ, those
categories were grouped. If no clear pattern was ob-
served for the primary outcomes, themedian was taken
as the cutoff point. The patients were censored at the
time of relapse, death, or last follow-up. OS and LFS
were calculated according to the Kaplan-Meier
method. Neutrophil and platelet recovery, aGVHD
and cGVHD occurrence, as well as TRM and relapse
incident (RI) were expressed as cumulative incidence
curves, in order to adjust the analysis for competing
risks. Death from any cause and graft rejection were
both competing risks to estimate the cumulative inci-
dence of aGVHD and cGVHD. Death in remission
was treated as a competing event to calculate the
cumulative incidence of relapse. Relapse was consid-
ered to be the competing event for calculating TRM.
The significance of differences between LFS curves
was estimated by the log-rank test (Mantel-Cox),
whereas Gray’s test was used to assess, in univariate
analyses, differences between RI and TRM [24]. All
variables having a P value\.20 in univariate analyses
were included in a multivariate analysis on LFS per-
formed using the Cox proportional regression model
[25], whereas the proportional subdistribution hazardregression model was used to perform multivariate
analyses of RI and TRM. To examine other possible
interactions, variables such as age, type of donor, dis-
ease status, cytogenetic remission, and period of trans-
plantation have been included in the multivariate
models for OS and LFS even if not statistically signif-
icant in univariate analyses. In the multivariate analy-
ses for RI and TRM, aGVHD has been considered
as a time-dependent covariate. P values\.05 were con-
sidered to be statistically significant. Statistical analysis
was performed using the SAS System (SAS inc, Cary,
NC), Stata software (StataCorp LP, College Station,
TX), the NCSS computer program (Hintze, 2001,
NCSS PASS, Number Crunched Statistical System,
Kaysville, UT), and R 2.5.0 software package.RESULTS
Engraftment and GVHD
Neutrophil and platelet engraftment occurred after
a median time of 18 days (range, 8-37) and 24 days
(range, 11-173) after HSCT, respectively. Neutrophil
engraftment forMFDandMUDtransplantation recip-
ients was obtained after 14 (range, 8-30) and 19 (range,
12-37) days, respectively (P 5 .018). Platelet engraft-
ment for MFD and MUD transplantation recipients
was reached after a median time of 23 (range, 11-81)
and 24 (range, 16-173) days, respectively (P 5NS).
Eighteen patients did not develop aGVHD (26%),
26 patients had grade I aGVHD (38%), 18 patients
had grade II aGVHD (26%), six patients presented
with grade III aGVHD(9%), andone patient developed
grade IV aGVHD (1%). The cumulative incidence of
grade II-IVaGVHDwas 36%(95%confidence interval
[CI], 26-50); it was 30% (95% CI, 18-49), and 44%
(95% CI, 30-65) for MFD and MUD transplantation
recipients, respectively (P 5NS).
Forty-five patients did not develop cGVHD
(74%), 10 patients presented with limited cGVHD
(10%), and six patients had extensive cGVHD (16%).
The cumulative incidence of cGVHD was 27% (95%
CI, 18-41); it was 18% (95%, CI 9-36) and 38%
(95% CI, 24-62) for MFD and MUD transplantation
recipients, respectively (P 5 .074).OS
The median follow-up time was 56 months (range,
4-218). The 5-year OS probability was 51% (95% CI,
38-63) (Figure 1). In univariate analyses, factors influ-
encing the probability of OS were donor type and pa-
tient gender. OS for MFD and MUD recipients was
62% (95% CI, 45-78) and 37% (95% CI, 18-56),
respectively (P 5 .04). The OS of females was 79%
(95% CI, 60-97) compared with 38% (95% CI,
22-53) for males (P 5 .01).
Figure 1. OS and LFS for children given a first allogeneic stem cell
transplantation.
Table 2. Results of Multivariate Analysis for Overall Survival
(OS), Leukemia-Free Survival (LFS), Relapse Incidence (RI),
and Transplantation-Related Mortality (TRM)
RR (95% CI) P value
Overall Survival
Gender
Male versus female 3.19 (0.88-11.54) .077
Disease phase
CR1 versus more advanced
disease
0.32 (0.14-0.74) .007
Donor type
MUD versus MFD 2.69 (1.13-6.42) .026
WBC count at diagnosis
$80  109/L versus <80  109/L 2.00 (0.90-4.45) .090
Year of transplantation
$2000 versus <2000 0.44 (0.16-1.19) .106
Cytogenetic remission
yes versus no 3.35 (0.68-16.51) .138
Age (continuous) 0.99 (0.90-1.09) .851
LFS
Gender
Male versus female 3.59 (1.03-12.59) .046
Disease phase
CR1 versus more advanced
disease
0.27 (0.12-0.61) .002
Donor type
MUD versus MFD 1.96 (0.86-4.45) .108
WBC count at diagnosis
$80  109/L versus <80  109/L 2.38 (1.11-5.12) .026
Year of transplantation
$2000 versus <2000 0.41 (0.16-1.07) .069
Cytogenetic remission
yes versus no 4.76 (0.98-23.18) .054
Age (continuous) 1.03 (0.94-1.135) .469
Relapse incidence
Gender
Male versus female 3.68 (1.28-10.56) .016
Molecular features
p210 versus p190 0.65 (0.18-2.31) .506
p190/p210 versus p190 4.72 (1.44-15.52) .011
Disease phase
CR1 versus more advanced
disease
0.31 (0.13-0.75) .009
Acute GVHD
Grade II-IV versus 0-I 0.26 (0.08-0.90) .033
Year of transplantation
$2000 versus <2000 0.79 (0.28-2.20) .653
Transplantation-related mortality
Gender
Male versus female 2.65 (0.45-15.52) .281
Molecular features
p210 versus p190 2.84 (0.62-13.11) .180
p190/p210 versus p190 0 0 <.0001
Disease phase
CR1 versus more advanced
disease
1.19 (0.29-4.78) .809
Acute GVHD
Grade II-IV versus 0-I 6.77 (1.40-32.63) .017
Year of transplantation
$2000 versus <2000 0.88 (0.21-3.73) .859
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transplantation (relative risk [RR] 5 0.32; 95% CI,
0.14-0.74; P 5 .007) and matched family donors
(RR 5 2.69, 95% CI, 1.13-6.42; P 5 .026) were con-
firmed as independent factors associated with a better
OS (Table 2).
LFS
The 5-year probability of LFS for all patients ana-
lyzed in the study was 47% (95% CI, 34-59)
(Figure 1). LFS was better for females compared with
males (74% [95% CI, 55-94] versus 34% [95% CI,
19-49], P 5 .006]) and for children who underwent
HSCTinCR1versus thosewhounderwent transplanta-
tion in CR2 or in a more advanced disease phase (56%
[95% CI, 40-73], 34% [95% CI 11-57], and 22%
[95%CI 0-49], respectively [P5 .008], Figure 2).Other
variables, such as conditioning regimen with or without
TBI, donor type, use of imatinib before or after HSCT,
cytogenetic status and aGVHD or cGVHD incidence,
had no impact on LFS (Supplementary Table 1).
In multivariate analyses, female gender (RR 5
3.59, [95% IC, 1.03-12.59], P 5 .046), early disease
phase at transplantation (RR 5 0.27 [95% CI, 0.12-
0.61], P 5 .002), and WBC count at diagnosis below
80  109/L (RR 5 2.38 [95% CI, 1.11-5.12],
P5 .026) were confirmed as independent factors asso-
ciated with a better LFS (Table 2).
RI
The median interval from HSCT to relapse was 7
months (range, 2-24). Considering the disease status at
HSCT, the median time to relapse was 10 months
(range, 3-17), 8months (range, 2-24), 3 months (range,
3-4), and 173 days (range, 128-238) for patients who
underwent transplantation in CR1, CR2, other CR
and not in remission, respectively (P 5 .05).
The overall RI for all patients who underwent
transplantation was 36% (95% CI, 26-50). In univari-ate analyses, RI was higher inmales (45% [95%CI, 32-
61]) than in females (16% [95%CI, 6-44]; P5 .01) and
in patients who underwent transplantation in more ad-
vanced disease phases (27% [95% CI, 16-45] in CR1
patients, 48%, [95% CI, 29-79] in CR2 patients, and
56%, [95% CI, 31-100] for patients with more ad-
vanced disease; P 5 .05) (Figure 3).
When we analyzed the specific bcr-abl transcripts,
namely, p190, p210, or the copresence of both, the RI
Figure 2. LFS according to remission status.
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80% (95% CI, 52-100), respectively (P 5 .057).
A trend for a lower probability of relapse was found
among patients with a WBC count at diagnosis below
80  109/L (22%, 95% CI 11-42) compared with
patients with a higher WBC count (45%, 95% CI
30-67; P 5 .07) and for patients who developed grade
II-IV aGVHD (20%, 95% CI 9-44) compared with
those who experienced grade 0-I aGVHD (45%,
95% CI 32-64; P 5 .06).
Other variables, such as cytogenetic abnormalities
other than t(9;22), the use of imatinib either before or
after HSCT, the donor type, the use of TBI in the
preparative regimen, and the occurrence of cGVHD
did not predict relapse in the univariate analysis
(Supplementary Table 2).
In multivariate analysis, the copresence of both
bcr-abl p190 and p210 transcripts (RR 5 4.72;
P 5 .01) and male gender (RR 5 3.68; P 5 .016)
were independent risk factors for relapse, whereas
early disease phase at transplantation (RR 5 0.31;
P 5 .009) and the occurrence of grade II-IV aGVHD
(RR 5 0.26; P 5 .033) were independent favorable
prognostic variables for RI (Table 2).TRM
The overall cumulative incidence of TRM was
17% (95% CI, 10-30). In univariate analyses, the
only factor significantly associated with an increased
risk of TRM was aGVHD: patients with grade II-IV
aGVHD had a TRM incidence of 32% (95% CI,
18-57) versus 9% (95% CI, 3-29) observed in patients
with grade 0-I aGVHD, respectively (P 5 .0071).
These data were confirmed by comparing patients
who experienced grade III-IV aGVHD with those
who experienced grade 0-II aGVHD, TRM being
43% (95% CI, 18-100) for the former and 15%
(95% CI, 7-29) for the latter (P 5 .049). None of the
other variables analyzed were associated with anincreased incidence of TRM (Supplementary Table
3). The proportional subdistribution hazard regres-
sion model confirmed the impact of grade II-IV
aGVHD on TRM (RR 5 6.77; P 5 .017).
Imatinib
Twenty-three patients were treated with imatinib
before HSCT and seven after HSCT. No significant
differences in terms of LFS, RI, or TRM were ob-
served among patients who did or did not receive im-
atinib, respectively.
Cytogenetics and Molecular Data
No differences were observed in terms of LFS, RI,
or TRM by comparing patients with isolated
Philadelphia-chromosome positive with those with ad-
ditional abnormalities. However, as mentioned previ-
ously, there was a higher RI for patients carrying both
p190 and p210 transcripts. In detail, four of the five pa-
tientswith the p190 andp210 transcripts relapsed (80%,
95% CI 52-100), compared with patients only with
p190 (33%, CI 95% 22-51) and p210 (31%, 95% CI
14-70; P 5 .057). This finding was also confirmed in
the multivariate analysis for RI (RR 5 4.72; P 5 .011).
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The main cause of treatment failure was disease
progression, which was recorded in 21 patients
(68%). Other causes of death were fungal infection
(3%), bacteria pneumonia (6%), interstitial pneumo-
nia (3%), cGVHD (3%), multiorgan failure (3%),
and finally, cerebral cryptococcosis (3%).
DISCUSSION
Although the majority of patients with Ph1 ALL
typically respond to first-line therapy, the duration of
remission is short in a vast proportion of patients. In
the past, the median EFS after combination chemo-
therapy was reported to be only approximately 8
months, with a 5-year OS of\20% [4,5]. Because of
this dismal outcome, allogeneic HSCT was
considered the optimal treatment after induction
chemotherapy for patients with a suitable MFD or
best-available MUD. Our report summarizes the
outcome of 69 pediatric and adolescent patients with
Ph1 ALL who underwent allogeneic HSCT in 13
AIEOP-HSCT centers from 1990 to 2008.
Our results demonstrate that many patients can be
cured provided that HSCT be performed early during
the course of the disease. Indeed, as already reported
by other groups [10,11,26], our results underscore
the importance of disease remission in determining
patients’ outcomes, as children who underwent
transplantation in CR1 fared significantly better in
terms of LFS than those who received HSCT in
a more advanced disease phase. The impact of
disease status (namely, morphologic CR1) on patient
outcome was independent of cytogenetic remission.
In this retrospective analysis of 69 children, we did
not observe any significant difference in the relapse
rate in patients who received imatinib therapy
compared with those who did not, even though the
negative result might be because of the low number
of patients who received imatinib mesylate. Our
results are, however, in agreement with data
produced by other groups who found no benefit of
imatinib mesylate on the outcome when HSCT is
performed in an early phase of disease [3].
The factors significantly correlated with a better
probability of LFS were being in CR1 at HSCT, fe-
male gender, and a WBC count at diagnosis\80 
109/L. Although the role of CR1 status has already
been outlined in a number of studies [13,26,27], the
impact of gender on outcome has emerged from very
few reports [28,29]. Because nearly two-thirds of pa-
tients were males, and given the limited number of pa-
tients, a nonrandom distribution of ‘‘high-risk’’
features (such as deletion of chromosome 9p) might
be the cause of these differences [30]. In particular,
other variables typically associated with a better out-
come, such as the donor type or the earlier phase ofdisease, did not show differences in the female versus
male cohorts (data not shown).
Other factors typically associated with LFS, in par-
ticular, cytogenetic remission at HSCT, the type of
donor employed, the use of TBI, or an occurrence of
aGVHD or cGVHD, had no significant effect [31-34].
The second aspect of our study to highlight is that
concerning leukemia recurrence and the graft-versus-
leukemia effect. Because a high proportion of relapsed
patients did not receive HSCT in CR1 (38%) and also
considering the low incidence of TRM (only 17% de-
spite an 18-year enrollment period), if a suitable donor
is identified, a low-intensity GVHDprophylaxis might
permit a more efficient immunologic effect in what is
an otherwise life-threatening disease, characterized
by a high incidence of relapse. This speculation is
supported by the lower RI observed in patients who
developed grade II-IV or III-IV aGVHD. Indeed, as
reported previously, patients with grade III-IV
GVHD had an RI of 14% compared with 39% for pa-
tients having grade 0-II GVHD. Thus, early HSCT
with a low-intensity GVHD prophylaxis might im-
prove the outcome. The advantage offered by the oc-
currence of GVHD in terms of disease recurrence
prevention was, however, offset by a higher incidence
of TRM, this resulting into a probability of LFS com-
parable in patients who did or did not experience
GVHD.However, more recent data produced by a co-
operative group (in imatinib-free patients), have shed
some light on the improved benefit of unrelated over
related transplantation for Ph1 ALL [26]. That study
showed a 5-year LFS rate of 41.4% 6 6.5% and
55.8% 6 5.4% before and after 2000 (P 5 .07) for
MUD recipients compared with 38.9% 6 6.6% and
41.1%6 6.4% forMFD (P5NS) forMFD recipients.
In the unrelated donor group, it was observed a lower
incidence of relapse (38.2% 6 6.4% and 21.4% 6
4.1% before and after 2000), whereas for the MFD
group, the cumulative incidence of relapse was un-
changed [26]. This finding could be attributed to
a more potent graft-versus-leukemia effect on residual
leukemia driven byHLAdisparities in the donor/recip-
ient pairs.
Our analysis shows how the outcome of patients is
related to molecular features, such as the specific p190
transcript and that LFS is significantly better than in
patients who also carry the p210 transcripts. These
data have already been established in adult populations
in which the p190 fusion was the only independent
prognostic factor conferring a significantly better
probability of DFS and OS. The heterogeneous clini-
cal outcome of bcr-abl ALL patients was first suggested
by Secker-Walker and Craig in 1993 [35,36], who
discussed the controversy surrounding a case of Ph1
ALL and an ALL blast crisis following Ph1 CML. A
favorable prognostic impact of the p190 gene fusion
on the clinical outcome of bcr-abl ALL patients was
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and 05/93 studies, in which only a trend toward a
better OS for the p1901 patients was noted [37-39].
Finally, the prognostic significance of bcr-abl
transcripts did not seem to be affected by the type of
transplantation procedure, as suggested by the results
of the multivariate analysis.
Since US Food and Drug Administration approval,
imatinib has become the upfront standard treatment for
both adults and children with Ph1 ALL, in the attempt
to obtain a better control of disease to improve out-
comes in patients receiving allogeneic HSCT. How-
ever, to date, the role of this therapeutic use of
Imatinib in a pediatric setting is still unclear and, for pe-
diatric patients with Ph1 ALL, there have only been
limited reports [40]. TheCOGrecently reported excel-
lent1-yearEFS rates in 31Ph1ALLpatients treatedon
the COG AALL0031 trial with intensive imatinib and
combination chemotherapy and 21 patients who re-
ceived MFD allogeneic HSCT after upfront chemo-
therapy and imatinib—both with superior results
(EFS 96.7% and 95%, respectively) comparedwith his-
toric controls [19]. Several reasons might explain why
imatinib did not significantly improve transplantation
outcomes in our and other Ph1 ALL cohorts [41,42]
such as: (1) proto-oncogene bcr-abl activity alone is
not responsible for the phenotype of Ph1 ALL [43],
(2) presence of imatinib-resistant clones [44], (3) ac-
quired resistance to imatinib also occurs, especially in-
volving the abl domain [45], (4) or the inability of
imatinib to eliminate the leukemia stem cell [46]. An-
other intriguing explanation for the nonbenefit of ima-
tinib on post-HSCT leukemia relapse has been given in
a recent article by Kang et al. [20], in which the result of
ALL MRD, monitored by gene profile, is a better pre-
dictor of leukemia relapse than the usual specific tran-
script. This would mean that other tumor escape
mechanisms are responsible for leukemia resistance
and the subsequent relapse of leukemia clones. By con-
trast, imatinib might extend the best time to transplan-
tation thus permitting, for patients lacking anMFD, the
search for and the recruitment of ‘‘the best’’ unrelated
HSCT donor while maintaining the remission status.
In conclusion, our data support performing alloge-
neic HSCT in pediatric Ph1 ALL as soon as a suitable
donor is found, especially if the specific p210 transcript
is identified at diagnosis. The role of imatinib follow-
ing HSCT should be investigated in a larger con-
trolled randomized study.ACKNOWLEDGMENTS
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